Topotecan – A Novel Topoisomerase I Inhibitor: Pharmacology and Clinical Experience

Publisher： Karger

E-ISSN： 1423-0232|56|1|1-12

ISSN： 0030-2414

Source： Oncology, Vol.56, Iss.1, 1999-01, pp. : 1-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New Advances in Lung Cancer Chemotherapy: Topotecan and the Role of Topoisomerase I Inhibitors

By  

Oncology, Vol. 61, Iss. 1, 2001-09 ,pp. : 14-24

Karger

Access to resources Recommend Favorite

The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl‐DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 7, 2015-07 ,pp. : 1858-1867

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase I Clinical Trial of Topotecan Given Every 2 Weeks in Patients with Refractory Solid Tumors

By  

Oncology, Vol. 61, Iss. 4, 2001-11 ,pp. : 265-270

Karger

Access to resources Recommend Favorite

Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 35, Iss. 11, 2015-11 ,pp. : 1037-1051

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacology

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 115, Iss. s1, 2014-07 ,pp. : 54-91

John Wiley & Sons Inc

Access to resources Recommend Favorite